How grading works
Every intervention carries an evidence tier from A to C. Tier is never signalled by colour alone: each card states the level in text, shows a three-segment confidence meter, and carries a coloured top stripe as a secondary cue.
Featured interventions
6 of 73 records- Category: GenomicsGenomicsINT-0001
Partial Epigenetic Reprogramming (OSK)
Mouse studies show restored vision, muscle and cognitive function; Altos Labs, Retro Biosciences and NewLimit pursuing translation. No human data yet.
Status
Preclinical; heavy industry investment
Level CEmerging evidence - Category: GenomicsGenomicsINT-0002
Telomerase Gene Therapy (AAV-hTERT)
Extended median lifespan in mice without raising cancer incidence in the original study; human use remains investigational and largely unregulated.
Status
Preclinical / early experimental
Level CEmerging evidence - Category: GenomicsGenomicsINT-0003
PCSK9 Base Editing
VERVE-101/-102 early-phase human data show durable LDL reduction — a proof of concept for one-and-done cardiovascular risk reduction relevant to healthspan.
Status
Phase I human data reported
Level CEmerging evidence - Category: GenomicsGenomicsINT-0004
Follistatin Gene Therapy
Robust muscle-preserving effects in animal models; human use confined to small experimental programs.
Status
Experimental
Level CEmerging evidence - Category: GenomicsGenomicsINT-0005
Klotho Upregulation
Higher Klotho associates with longevity and cognition in humans; delivery approaches (gene therapy, secretagogues) are preclinical.
Status
Preclinical
Level CEmerging evidence - Category: GenomicsGenomicsINT-0006
CRISPR Somatic Gene Editing
Rapid clinical progress in targeted indications (transthyretin amyloidosis, NTLA-2001) proves durable in-vivo editing is feasible; broad aging application remains aspirational.
Status
Late-stage in specific diseases; aging use conceptual
Level CEmerging evidence